Elevate Capital Buys Egypt's Nile Radiology in $19.5M Deal, Eyes AI-Driven Diagnostics and EGX Listing

Elevate Capital and members of the Moharram family have signed a definitive agreement to acquire full ownership of Nile Radiology and Labs, one of Egypt's longest-standing diagnostic imaging networks, in a deal valued at roughly USD 19.5 million (EGP 1 billion).

The transaction covers 100% of the company, which was founded nearly three decades ago by the late Dr. Hazem Moharram. Today, Nile Radiology and Labs operates more than 20 diagnostic centers across Egypt and serves over 150,000 patients annually, making it a significant player in the country's private healthcare infrastructure.

The deal still needs to clear customary regulatory approvals and closing conditions before it is finalized, a standard requirement for transactions of this scale in Egypt's healthcare sector.

A Strategic Fit for Elevate's Healthcare Portfolio

Nile Radiology and Labs joins a healthcare portfolio that Elevate Capital has been steadily building, which already includes Gustave Roussy International Egypt, New Giza University Hospital, Nile Health Pharmacies, and a set of outpatient and specialized care platforms. Adding an established diagnostics network with national reach gives the firm a broader footprint across the patient care continuum, from hospitals and pharmacies to imaging and lab testing.

Elevate Capital has outlined plans to grow the acquired business through geographic expansion, additional selective acquisitions, and digital transformation efforts. Notably, the firm intends to invest in AI-enhanced diagnostics, a move that reflects a broader trend among healthcare operators in emerging markets to use machine learning tools for faster image analysis and more consistent diagnostic accuracy at scale.

Eyes on a Public Listing

Beyond operational growth, the consortium behind the deal says it will study the possibility of listing Nile Radiology and Labs on the Egyptian Exchange (EGX). Such a move would mark a notable step for the company, transitioning from a family-founded diagnostics chain into a publicly traded healthcare entity, and could set a precedent for how private equity-backed healthcare assets exit or scale in Egypt's capital markets.

The acquisition arrives at a moment when Egypt's private healthcare sector is attracting increased investor interest, driven by rising demand for diagnostic services and a push toward consolidating fragmented networks of clinics and labs into larger, more efficient platforms. For Elevate Capital, folding Nile Radiology and Labs into its existing portfolio strengthens its position as one of the more active consolidators in the region's healthcare space, while the AI-diagnostics ambition signals where much of the sector's next wave of investment is likely to be directed.

No specific timeline has been given for either the regulatory approval process or the potential EGX listing study, leaving both as developments to track in the coming months.